Qianjiang Yongan Pharmaceutical Co., Ltd. Class A
SSZSE:00236511.27
CNY
+0.09
(+0.81%)
ISIN
CNE100000LZ9
Return %
Stock
S&P 500
1Y
-35.75
13.14
3Y
16.67
80.78
5Y
27.06
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Ren Gui Hong
- Full Time Employees
- 912
- Sector
- Process industries
- Industry
- Chemicals: specialty
- Address
- No. 2 Guangze Avenue Qianjiang HB China 433132
- IPO Date
- Feb 12, 2010
- Website
- chinataurine.com
- Similar Companies
- Business
- Qianjiang Yongan Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of taurine and related pharmaceutical products. The company offers a comprehensive portfolio including medical taurine and food additive grade taurine, ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, creatine monohydrate, and various health products. Its taurine products serve multiple applications in medicines, food additives, feed, surface active agents, and whitening agents. The company operates primarily in China but also has a broad international market presence spanning Africa, Asia, Australia, Central and South America, Eastern Europe, the Middle East, North America, and Western Europe. Founded in 2001, Qianjiang Yongan Pharmaceutical is headquartered in Qianjiang, China. In the most recent major developments, the company completed a strategic acquisition in September 2025 by using 27 million yuan of its own capital to acquire the remaining 49.20% shares of its holding subsidiary Hubei Ling'an Technology Co., Ltd., thereby becoming the sole owner. This acquisition further consolidates its technological and production capabilities without altering the scope of its consolidated financial statement. Despite operational and market challenges reported in early 2025, including a temporary net loss in Q1 2025, the company continues to affirm stable production and business operations. The company has not engaged in direct online or cross-border e-commerce sales for taurine but utilizes a mixed sales model combining agent distribution and direct sales to end customers. The chairman faced investigation and detention in 2025 but has since been released, with ongoing normal company operations assured. Qianjiang Yongan Pharmaceutical holds multiple certifications including GMP, ISO9001, ISP22000, kosher, halal, FAMI-QS, and BRC, underscoring its compliance with international quality and safety standards. The company's extensive taurine production capacity of approximately 38,000 metric tons per year establishes it as a leading global taurine manufacturer. It participates actively in global trade exhibitions and promotes product innovation aimed at diverse industries such as pharmaceuticals, food, and animal feed additives. Overall, Qianjiang Yongan Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical company with a specialized focus on taurine and related chemical products, supported by recent strategic acquisitions and continued operational resilience since its founding in 2001 in Qianjiang, China.